000 02679nam a2200193 4500
003 OSt
005 20200105020006.0
008 190729b xxu||||| |||| 00| 0 eng d
020 _a9780062338785
020 _c006233879X
100 1 _aEban, Katherine
245 1 0 _aBottle of lies
_bthe inside story of the generic drug boom
_cKatherine Eban.
250 _aFirst edition.
260 _aNew York, NY
_bEcco, an imprint of HarperCollins Publishers
300 _axxiv, 482 pages ;
_c24 cm.
505 _aPart I: Shifting ground. The man who saw further ; The gold rush ; A slum for the rich ; The language of quality ; Red flags -- Part II: India rises. Freedom fighters ; One dollar a day ; A clever way of doing things ; The assignment -- Part III: A cat-and-mouse business. The global cover-up ; Map of the world ; The pharaoh of pharma -- Part IV: Making a case. Out of the shadows ; "Do not give to FDA" ; "How big is the problem?" ; Diamond and ruby ; "You just don't get it" -- Part V: Detectives in the dark. Congress wakes up ; Solving for X ; A test of endurance ; A deep, dark well ; The $600 million jacket -- Part VI: The watershed. The light switch ; We are the champions ; Crashing files ; The ultimate testing laboratory -- Part VII: Reckonings. Flies too numerous to count ; Standing.
520 _a"Many have hailed the widespread use of generic drugs as one of the most important public-health developments of the twenty-first century. Today, almost 90 percent of our pharmaceutical market is comprised of generics, the majority of which are manufactured overseas. We have been reassured by our doctors, our pharmacists and our regulators that generic drugs are identical to their brand-name counterparts, just less expensive. But is this really true? Katherine Eban's Bottle of Lies exposes the deceit behind generic-drug manufacturing--and the attendant risks for global health. Drawing on exclusive accounts from whistleblowers and regulators, as well as thousands of pages of confidential FDA documents, Eban reveals an industry where fraud is rampant, companies routinely falsify data, and executives circumvent almost every principle of safe manufacturing to minimize cost and maximize profit, confident in their ability to fool inspectors. Meanwhile, patients unwittingly consume medicine with unpredictable and dangerous effects. The story of generic drugs is truly global. It connects middle America to China, India, sub-Saharan Africa and Brazil, and represents the ultimate litmus test of globalization: what are the risks of moving drug manufacturing offshore, and are they worth the savings?" -- Dust jacket.
942 _2NLM
999 _c41002